Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry

Bohn, Barbara; Zimmermann, A; Wagner, Christian von; Merger, Sigrun; Dunstheimer, Desirée; Kopp, Florian; Gollisch, Katja; Zindel, Volker; Holl, Reinhard W.; Initiative, Dpv

doi:10.1016/j.diabres.2017.03.031

Cited by 15 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The switch from IGlar to IDeg in our patients allowed a significant reduction of the number of daily insulin injections at the end of follow-up. These findings, already reported in adults with T1D ( 29 ), are important considering that insulin effectiveness can be reduced by several factors related to patients' practices in taking their daily dose.…”

Section: Discussionsupporting

confidence: 63%

Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes

et al. 2018

View full text Add to dashboard Cite

Background/Objective: Insulin degludec (IDeg) is an ultra-long-acting analog with less daily variability compared to other basal insulins. In this retrospective study we examined 1-year efficacy and safety of IDeg in youth with type 1 diabetes (T1D).Subjects/Methods: Thirty-seven patients [11.7 ± 4.22 years; T1D duration 4.97 ± 3.63 years; once-daily glargine (IGlar) by at least 1 year] were switched to once-daily IDeg because of glycosylated hemoglobin (HbA1c) >7.5% and/or reported physical pain at IGlar injection. Changes in HbA1c, 30-day mean fasting plasma glucose (mean FPG), daily insulin dose, and severe hypoglycemia rates were collected at basal insulin switch (T0), 3-months (T1), 6-months (T2), and 12-months (T3) after IDeg was started.Results: In patients with HbA1c >7.5% at T0 we found a decrease in HbA1c values (%) from 8.46 ± 0.53 to 7.89 ± 0.72 at T1 (p = 0.008) and 7.97 ± 0.89 at T2 (p = 0.035). At T3, 38.9% of patients had HbA1c ≤ 7.5%. Mean FPG levels significantly decreased at T2 (p = 0.043). In the overall study population, we documented an increase in IDeg dose (+12.5% at T3; p < 0.001) and a decrease in mealtime insulin dose (−11.6% at T3; p = 0.001) after switch. HbA1c levels were unchanged. No episode of severe hypoglycemia was reported.Conclusions: Our data in children and adolescents with T1D suggest that IDeg dose should be increased by 12% and mealtime insulin doses should be lowered by 11% for patients who previously received IGlar. IDeg might be considered useful and well tolerated and it seems to improve the glycemic control compared to IGlar, mainly in patients with poor glycemic control.

show abstract

Section: Discussionsupporting

confidence: 63%

Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The BMI increased from 23.2 to 24.0 kg/m 2 in patients with T1DM who had switched to IDeg (p \ 0.0001). This was observed in all subgroups with the exception those with prior insulin NPH use [14].…”

Section: Lispro Protaminementioning

confidence: 66%

Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety

Ponzani¹,

Berra²,

Lelio

et al. 2019

Diabetes Ther

View full text Add to dashboard Cite

Introduction: Real-world evidence on the effectiveness and safety of insulin degludec (IDeg) in patients with diabetes is a priority. We have therefore evaluated the effectiveness and safety of IDeg, including impact on metabolic control, glycemic variability, weight gain and hypoglycemia, in patients with type 1 diabetes under routine clinical practice conditions. Methods: This was an observational longitudinal multicenter study. A retrospective chart review of Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.10042994.

show abstract

“…To our knowledge, only one such retrospective study exploring the change of insulin doses after switch to degludec is available so far. It is a survey on 360 patients with type 1 diabetes, reporting a reduction of basal insulin dose in those switching from detemir to degludec, but not in patients switching from glargine to degludec [25]. Due to its shorter duration of action, detemir is used twice daily in type 1 diabetes more often than glargine [26,27]; unfortunately, in the retrospective study reported above, no separate analysis was performed on patients previously treated with basal insulin either once or twice daily.…”

Section: Discussionmentioning

confidence: 99%

Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study

Lualdi

Silverii

Dicembrini

et al. 2018

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry

Cited by 15 publications

References 24 publications

Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes

Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes

Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety

Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study

Contact Info

Product

Resources

About